Further Experience With Catheter Closure of Patent Ductus Arteriosus Using the New Amplatzer Duct Occluder in Children

Thanopoulos, Basil Vasilios D; Eleftherakis, Nikolaos G; Tzannos, Konstantinos; Stefanadis, Christodoulos; Giannopoulos, Andreas A.

doi:10.1016/j.amjcard.2009.11.030

Cited by 38 publications

(37 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another common complication of percutaneously Amplatzer PDA closure is left pulmonary artery (LPA) obstruction 3512131819212223. The reported rate of LPA stenosis varies, between 0-12% 121624…”

Section: Discussionmentioning

confidence: 99%

Experience with percutaneous closure of ductus arteriosus using the Amplatzer duct occluder in 243 consecutive patients and long-term results-A single centre study

Behjati-Ardakani

Hadadzadeh

et al. 2014

Niger Med J

View full text Add to dashboard Cite

Background:Percutaneous closure of patent ductus arteriosus (PDA) with Amplatzer duct occluder (ADO) has become increasingly popular in many cardiovascular centres. This study analysed the long-term results of percutaneous closure of PDA with ADO in a single centre.Materials and Methods:Between May 2004 and January 2013, 243 patients with median age of 2.5 years (range = 30 months to 38 years) and median weight of 10 Kg (range 4.5–80.5 Kg) underwent percutaneous closure of PDA using the ADO. The devices were implanted under fluoroscopic guidance. Patients were followed-up for any complications.Results:The mean diameter of narrow part of PDA was 6.4 ± 2.2 mm. The mean diameter of devices was 7.8 ± 2.3 mm. The devices were successfully implanted in 239 (98.3%) cases. At immediate, 1 day, 1, 6, 12 months and late follow-up, the complete occlusion rate was 33% (79 case), 97.1% (236 case), 97.5% (237 case), 98.3% (238 case), 98.3% (238 case) and 98.3% (238 case), respectively. Residual shunt remained in one case at late follow-up. The device embolisation occurred in five patients. The devices were successful retrieved in three patient and second larger devices were inserted. Two other devices were surgically retrieved and PDAs were ligated. Moderate left pulmonary artery stenosis (LPA) in one child and mild LPA stenosis in one infant were detected. Mild aortic obstruction occurred in one infant.Conclusions:Long-term follow-up of patients indicate that percutaneous closure of PDA using ADO is a safe and effective procedure. However, some complications, including device embolisation, left pulmonary stenosis and aortic obstruction may be observed in some cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Experience with percutaneous closure of ductus arteriosus using the Amplatzer duct occluder in 243 consecutive patients and long-term results-A single centre study

Behjati-Ardakani

Hadadzadeh

et al. 2014

Niger Med J

View full text Add to dashboard Cite

show abstract

“…Due to advances in diagnostic and therapeutic modalities diagnosis and treatment of PDA can be accomplished at a relatively early age [5][6][7] . Thanopoulos et al 14 reported success rates of 95% and 98% soon after and one month after device implantation in patients with a mean age of 3.6 years.…”

Section: Discussionmentioning

confidence: 99%

“…The ADO2 device provides a solution for the closure of small to moderate-sized PDAs in children 13,14 . We have demonstrated that percutaneous treatment with ADO2 can be realized with lower complication and residual shunt rates.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early clinical experience with the new Amplatzer Ductal Occluder II for closure of the persistent arterial duct

Goonetilleke¹,

Jayarathna²,

Inthisar³

et al. 2014

Sri Lanka J Child Health

View full text Add to dashboard Cite

Objective: To describe early single-centre clinical experience with the Amplatzer Ductal Occluder II (ADO II).Method: Children with a haemodynamically significant patent ductus arteriosus (PDA) who underwent percutaneous trans-pulmonary closure with Amplatzer Ductal Occluder II (ADO2) were included. Data was collected from computer based patient records.Results: Trans-pulmonary PDA closures using ADO 2 were undertaken in 32 children (22 females) with a mean age of 1year 9 months (range 5 months to 10 years) and a mean weight of 8.2kg (range 4.2-25kg). Complete occlusion was noted pre-discharge in 31 (97%) patients. One (3%) had residual shunting after deployment followed by embolization to the left pulmonary artery on the third day of the procedure. One (3%) had mild flow acceleration in the left pulmonary artery and another (3%) had mild aortic flow obstruction following the procedure. At 7 and 30 days, echocardiography confirmed complete ductal occlusion without need for further intervention in all 31 (97%) successful cases.Conclusion: ADO II is highly effective in rapid occlusion of morphologically varied small to moderate-sized PDAs.

show abstract

“…It is shaped in sequential lobes characterized by two low-profile retention discs and a connecting waist. Flexibility of the articulations allows this device to simplify the treatment in a range of patients and specific defect anatomies that are more challenging [1–3]. …”

Section: Introductionmentioning

confidence: 99%

Transcatheter closure of ventricular septal defects using the Amplatzer Duct Occluder II device: a single-center experience

Polat¹,

Türkmen²

2016

pwki

View full text Add to dashboard Cite

IntroductionOff-label use of different devices has been described for percutaneous closure of ventricular septal defects (VSD) because of the unacceptable rate of post-procedure heart block associated with special VSD devices.AimTo describe the early single-center clinical experience with closure of a VSD using the Amplatzer Duct Occluder II (ADO II) device in children.Material and methodsBetween May 2013 and June 2015, 26 patients between 13 days and 16 years of age underwent percutaneous closure of a VSD with an ADO II device at our institute. The decision to use the ADO II device was based primarily on lower risk of total atrioventricular block (TAVB) after VSD closure reported in the literature, reduction of the cost of the procedure and the need to close symptomatic VSDs in young patients.ResultsThe location of the VSD was perimembranous in 21 patients, postsurgical residual in 2, midmuscular in 2 and apical muscular in 1. Complex procedures including newborn, combined procedures and postsurgical residual VSD were performed in 5 (19%) patients. The median duration of follow-up was 12 months. The complete VSD closure rate was 81% immediately after the procedure, 85% at 24 h, and 93% at the last follow-up. There was no device embolization. During the entire follow-up period, TAVB did not develop.ConclusionsThe ADO II constitutes a safe and effective therapeutic alternative for morphologically varied VSDs in all pediatric age groups. A larger range of sizes and configurations of this occluder may be required to successfully occlude a wider range of VSDs.

show abstract

Further Experience With Catheter Closure of Patent Ductus Arteriosus Using the New Amplatzer Duct Occluder in Children

Cited by 38 publications

References 7 publications

Experience with percutaneous closure of ductus arteriosus using the Amplatzer duct occluder in 243 consecutive patients and long-term results-A single centre study

Experience with percutaneous closure of ductus arteriosus using the Amplatzer duct occluder in 243 consecutive patients and long-term results-A single centre study

Early clinical experience with the new Amplatzer Ductal Occluder II for closure of the persistent arterial duct

Transcatheter closure of ventricular septal defects using the Amplatzer Duct Occluder II device: a single-center experience

Contact Info

Product

Resources

About